phrykt

Royalty Pharma (RPRX) debt: $9B

Royalty Pharma had $9B of long-term debt on Dec 31, 2025, including the part due within a year, up 17.6% from $7.6B a year earlier.

From Royalty Pharma's filings with the SEC · Read the filing · RPRX stock page

Royalty Pharma debt by year

$7.1B2021$7.1B2022$6.1B2023$7.6B2024$9B2025

#195 of 2,129 US companies by debt · See the full ranking

Year endedDebtChange
Dec 31, 2025$9B+18%
Dec 31, 2024$7.6B+24%
Dec 31, 2023$6.1B-14%
Dec 31, 2022$7.1B+0%
Dec 31, 2021$7.1B–

Debt of similar companies

Companies in the same industry as Royalty Pharma, by SEC industry code, with the closest debt. Each name opens the same page for that company.

CompanyDebt, latest yearYear ended
Bausch Health Companies$20.8BDec 31, 2025
Viatris$14.4BDec 31, 2025
Abbott Laboratories$12.9BDec 31, 2025
Zoetis$9BDec 31, 2025
Royalty Pharma$9BDec 31, 2025
Organon$8.6BDec 31, 2025
Jazz Pharmaceuticals$5.4BDec 31, 2025

Questions and answers

What is Royalty Pharma's debt?

Royalty Pharma had $9B of long-term debt on Dec 31, 2025, including the part due within a year, up 17.6% from $7.6B a year earlier.

Numbers as reported in Royalty Pharma's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology